• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

内皮型一氧化氮合酶在四氯化碳诱导的肝纤维化模型中门静脉高压发展中的作用。

Role of endothelial nitric oxide synthase in the development of portal hypertension in the carbon tetrachloride-induced liver fibrosis model.

机构信息

Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA.

出版信息

Am J Physiol Gastrointest Liver Physiol. 2009 Oct;297(4):G792-9. doi: 10.1152/ajpgi.00229.2009. Epub 2009 Jul 23.

DOI:10.1152/ajpgi.00229.2009
PMID:19628654
Abstract

Portal hypertension (PHT) is a complication of liver cirrhosis and directly increases mortality and morbidity by increasing the propensity of venous hemorrhage. There are two main underlying causations for PHT, increased hepatic resistance and systemic hyperdynamic circulation. Both are related to localized aberrations in endothelial nitric oxide synthase (eNOS) function and NO biosynthesis. This study investigates the importance of eNOS and systemic hyperdynamic-associated hyperemia to better understand the pathophysiology of PHT. Wild-type and eNOS(-/-) mice were given the hepatotoxin CCl(4) for 4-12 wk. Hepatic fibrosis was determined histologically following collagen staining. Portal venous pressure, hepatic resistance, and hyperemia were determined by measuring splenic pulp pressure (SPP), hepatic portal-venous perfusion pressure (HPVPP), abdominal aortic flow (Qao), and portal venous flow (Qpv). Hepatic fibrosis developed equally in wild-type and eNOS(-/-) CCl(4)-exposed mice. SPP, Qao, and Qpv increased rapidly in wild-type CCl(4)-exposed mice, but HPVPP did not. In eNOS(-/-) CCl(4) mice, Qao was not increased, SPP was partially increased, and HPVPP and Qpv were increased nonsignificantly. We concluded that the systemic hyperemia component of hyperdynamic circulation is eNOS dependent and precedes increased changes in hepatic resistance. Alternative mechanisms, possibly involving cyclooxygenase, may contribute. eNOS maintains normal hepatic resistance following CCl(4)-induced fibrosis. Consequently, increased portal pressure following chronic CCl(4) exposure is linked to hyperdynamic circulation in wild-type mice and increased hepatic resistance in eNOS(-/-) mice.

摘要

门静脉高压症(PHT)是肝硬化的并发症,通过增加静脉出血的倾向直接增加死亡率和发病率。PHT 的两个主要潜在病因是肝内阻力增加和全身高动力循环。这两者都与内皮型一氧化氮合酶(eNOS)功能和 NO 生物合成的局部异常有关。本研究旨在研究 eNOS 和与全身高动力相关的高血容量对更好地理解 PHT 病理生理学的重要性。野生型和 eNOS(-/-)小鼠接受肝毒素 CCl(4)处理 4-12 周。胶原染色后通过组织学确定肝纤维化。通过测量脾髓压(SPP)、肝门静脉-静脉灌注压(HPVPP)、腹主动脉流量(Qao)和门静脉流量(Qpv)来确定门静脉压力、肝内阻力和高血容量。野生型和 eNOS(-/-)CCl(4)暴露的小鼠中肝纤维化的发展程度相同。SPP、Qao 和 Qpv 在野生型 CCl(4)暴露的小鼠中迅速增加,但 HPVPP 没有增加。在 eNOS(-/-)CCl(4)小鼠中,Qao 没有增加,SPP 部分增加,HPVPP 和 Qpv 增加不显著。我们得出结论,高动力循环的全身高血容量成分依赖于 eNOS,并且先于肝内阻力的变化。可能涉及环氧化酶的替代机制可能会有所贡献。eNOS 维持 CCl(4)诱导的纤维化后正常的肝内阻力。因此,慢性 CCl(4)暴露后门静脉压力的增加与野生型小鼠的高动力循环和 eNOS(-/-)小鼠的肝内阻力增加有关。

相似文献

1
Role of endothelial nitric oxide synthase in the development of portal hypertension in the carbon tetrachloride-induced liver fibrosis model.内皮型一氧化氮合酶在四氯化碳诱导的肝纤维化模型中门静脉高压发展中的作用。
Am J Physiol Gastrointest Liver Physiol. 2009 Oct;297(4):G792-9. doi: 10.1152/ajpgi.00229.2009. Epub 2009 Jul 23.
2
Thalidomide ameliorates portal hypertension via nitric oxide synthase independent reduced systolic blood pressure.沙利度胺通过不依赖一氧化氮合酶降低收缩压来改善门静脉高压。
World J Gastroenterol. 2015 Apr 14;21(14):4126-35. doi: 10.3748/wjg.v21.i14.4126.
3
Liposome-mediated gene transfer of endothelial nitric oxide synthase to cirrhotic rat liver decreases intrahepatic vascular resistance.脂质体介导的内皮型一氧化氮合酶基因转移至肝硬化大鼠肝脏可降低肝内血管阻力。
J Gastroenterol Hepatol. 2008 Aug;23(8 Pt 2):e487-93. doi: 10.1111/j.1440-1746.2007.05244.x. Epub 2007 Dec 7.
4
Role of nitric oxide synthase and cyclooxygenase in hyperdynamic splanchnic circulation of portal hypertension.一氧化氮合酶和环氧化酶在门静脉高压高动力内脏循环中的作用。
Hepatobiliary Pancreat Dis Int. 2008 Oct;7(5):503-8.
5
Transplantation of endothelial progenitor cells ameliorates vascular dysfunction and portal hypertension in carbon tetrachloride-induced rat liver cirrhotic model.内皮祖细胞移植可改善四氯化碳诱导的大鼠肝硬变模型中的血管功能障碍和门脉高压。
J Gastroenterol Hepatol. 2013 Jan;28(1):168-78. doi: 10.1111/j.1440-1746.2012.07238.x.
6
Murine study of portal hypertension associated endothelin-1 hypo-response.门静脉高压相关内皮素-1低反应的小鼠研究
World J Gastroenterol. 2015 Apr 28;21(16):4817-28. doi: 10.3748/wjg.v21.i16.4817.
7
Comparison of vascular nitric oxide production and systemic hemodynamics in cirrhosis versus prehepatic portal hypertension in rats.肝硬化与大鼠肝前性门静脉高压症中血管一氧化氮生成及全身血流动力学的比较
Hepatology. 1996 Oct;24(4):947-51. doi: 10.1002/hep.510240432.
8
Deleterious effects of silymarin on the expression of genes controlling endothelial nitric oxide synthase activity in carbon tetrachloride-treated rat livers.
Life Sci. 2009 Aug 12;85(7-8):281-90. doi: 10.1016/j.lfs.2009.06.001. Epub 2009 Jun 13.
9
Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.白藜芦醇可改善肝硬化大鼠肝内内皮功能障碍,并减少肝纤维化和门脉压。
J Hepatol. 2013 May;58(5):904-10. doi: 10.1016/j.jhep.2012.12.012. Epub 2012 Dec 20.
10
Simvastatin effects on portal-systemic collaterals of portal hypertensive rats.辛伐他汀对门静脉高压大鼠门体侧支循环的影响。
J Gastroenterol Hepatol. 2010 Aug;25(8):1401-9. doi: 10.1111/j.1440-1746.2009.06159.x.

引用本文的文献

1
Deciphering Molecular Mechanisms of Carbon Tetrachloride- Induced Hepatotoxicity: A Brief Systematic Review.解读四氯化碳诱导肝毒性的分子机制:简要系统综述
Curr Mol Med. 2024;24(9):1124-1134. doi: 10.2174/0115665240257603230919103539.
2
Current and investigational drugs in early clinical development for portal hypertension.门静脉高压早期临床开发中的现有药物和研究性药物。
Front Med (Lausanne). 2022 Oct 10;9:974182. doi: 10.3389/fmed.2022.974182. eCollection 2022.
3
Metabolomic Characterization of Human Model of Liver Rejection Identifies Aberrancies Linked to Cyclooxygenase (COX) and Nitric Oxide Synthase (NOS).
肝移植排斥反应人类模型的代谢组学特征鉴定出与环氧化酶(COX)和一氧化氮合酶(NOS)相关的异常。
Ann Transplant. 2019 Jun 11;24:341-349. doi: 10.12659/AOT.913800.
4
The multi-kinase inhibitor pazopanib targets hepatic stellate cell activation and apoptosis alleviating progression of liver fibrosis.多激酶抑制剂帕唑帕尼靶向肝星状细胞活化和凋亡,减轻肝纤维化进展。
Naunyn Schmiedebergs Arch Pharmacol. 2015 Dec;388(12):1293-304. doi: 10.1007/s00210-015-1157-7. Epub 2015 Aug 14.
5
Murine study of portal hypertension associated endothelin-1 hypo-response.门静脉高压相关内皮素-1低反应的小鼠研究
World J Gastroenterol. 2015 Apr 28;21(16):4817-28. doi: 10.3748/wjg.v21.i16.4817.
6
Glycyrrhizinate reduces portal hypertension in isolated perfused rat livers with chronic hepatitis.甘草酸降低慢性肝炎大鼠离体灌流肝脏的门静脉高压。
World J Gastroenterol. 2013 Sep 28;19(36):6069-76. doi: 10.3748/wjg.v19.i36.6069.
7
Current concepts on the role of nitric oxide in portal hypertension.目前关于一氧化氮在门静脉高压中的作用的概念。
World J Gastroenterol. 2013 Mar 21;19(11):1707-17. doi: 10.3748/wjg.v19.i11.1707.
8
Salvianolic Acid B reducing portal hypertension depends on macrophages in isolated portal perfused rat livers with chronic hepatitis.丹酚酸 B 通过调节枯否细胞减轻慢性肝炎大鼠肝脏储备功能的损伤
Evid Based Complement Alternat Med. 2012;2012:786365. doi: 10.1155/2012/786365. Epub 2012 Oct 16.
9
Mechanisms of hepatic fibrogenesis.肝纤维化的发生机制。
Best Pract Res Clin Gastroenterol. 2011 Apr;25(2):195-206. doi: 10.1016/j.bpg.2011.02.005.
10
Tumor necrosis factor alpha signaling in the development of experimental murine pre-hepatic portal hypertension.肿瘤坏死因子α信号在实验性小鼠肝前门静脉高压症发展中的作用
Int J Physiol Pathophysiol Pharmacol. 2010 Mar 8;2(2):104-110.